Market Pipeline Report Peanut Allergy Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Oncology) pipeline landscape. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. —
Browse the 23 Tables and 11 Figures, 12 Company Profiles, Spread across 84 Pages Report Available at http://www.reportsnreports.com/reports/992907-peanut-allergy-pipeline-review-h1-2017.html .
Peanut Allergy market companies are Adverum Biotechnologies Inc, Aimmune Therapeutics Inc, Alfacyte Ltd, Allergy Therapeutics Plc,AnaptysBio Inc, ASIT Biotech SA, Astellas Pharma Inc, BioLingus AG,DBV Technologies SA,HAL Allergy BV, Intrommune Therapeutics, Sanofi.
All Drug Profiles are Allergen, ANB-020, ANN-004, AR-101, ASP-0892, DBV-712, HALMPE-1, INT-301, PER-1080, pnut-ASIT, Polyvac Peanu, SAR-439794, SCV-204, SCV-209, Vaccine 2, VTC-064.
Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.
Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992907
The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.
• The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
• The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Discount of this report http://www.reportsnreports.com/contacts/discount.aspx?name=992907
Reasons to buy
• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Name: Ritesh Tiwari
Email: Send Email
Release ID: 198628